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Abstract: 
Background. Cognitive dysfunction is a core feature of psychotic disorders; however, substantial 
variability exists both within and between subjects in terms of cognitive domains of dysfunction, 
and a clear ‘profile’ of cognitive strengths and weaknesses characteristic of any diagnosis or 
psychosis as a whole has not emerged. Cluster analysis provides an opportunity to group 
individuals using a data-driven approach rather than predetermined grouping criteria. While 
several studies have identified meaningful cognitive clusters in schizophrenia, no study to date 
has examined cognition in a cross-diagnostic sample of patients with psychotic disorders using a 
cluster approach. We aimed to examine cognitive variables in a sample of 167 patients with 
psychosis using cluster methods. 
Method. Subjects with schizophrenia (n = 41), schizo-affective disorder (n = 53) or bipolar 
disorder with psychosis (n = 73) were assessed using a battery of cognitive and clinical 
measures. Cognitive data were analysed using Ward's method, followed by a K-means cluster 
approach. Clusters were then compared on diagnosis and measures of clinical symptoms, 
demographic variables and community functioning. 
Results. A four-cluster solution was selected, including a ‘neuropsychologically normal’ cluster, 
a globally and significantly impaired cluster, and two clusters of mixed cognitive profiles. 
Clusters differed on several clinical variables; diagnoses were distributed amongst all clusters, 
although not evenly. 
Conclusions. Identification of groups of patients who share similar neurocognitive profiles may 
help pinpoint relevant neural abnormalities underlying these traits. Such groupings may also 
hasten the development of individualized treatment approaches, including cognitive remediation 
tailored to patients' specific cognitive profiles. 
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Introduction 
Cognitive dysfunction is a core feature of all psychotic disorders; however, substantial variability 
exists in terms of cognitive domains of dysfunction – both within and between diagnostic 
groupings – and a clear ‘profile’ of cognitive strengths and weaknesses has not emerged (e.g. 
Goldstein, 1990; Seaton et al.2001). Cluster analysis provides an opportunity to group 
individuals using a data-driven approach rather than pre-determined grouping criteria (e.g. 
diagnosis). Such approaches permit individuals to be classified based not on single variables or 
factors but on patterns or profiles of traits, creating the potential for more homogeneous 
groupings than single domains or predefined categories. 
Cluster-analytic studies of neurocognition in patients with schizophrenia (SZ) suggest that 
meaningful groupings emerge using this data-reduction approach (for a review, see Seaton et 
al.2001). The most consistent findings on subgroups include a cluster of patients with a 
‘neuropsychologically normal’ profile, a cluster with widespread and significant deficits, and one 
to three intermediate profiles of mixed cognitive deficits (Heinrichs & Awad,1993; Goldstein & 
Shemansky, 1995; Goldstein et al.1996, 1998, 2005; Palmer et al.1997; Seaton et al.1999; Hill et 
al.2002; Allen et al.2003). These findings suggest that, while most patients with SZ suffer from 
significant and/or widespread cognitive impairment, a subset of patients with SZ exhibits 
cognitive functioning that is similar to that of the general population. 
Findings regarding intermediate or mixed clusters are more heterogeneous. Heinrichs & Awad 
(1993) found a five-cluster solution including three mixed clusters with relatively selective 
deficits (executive-prefrontal dysfunction, executive-motor deficits, and selective motor deficits). 
Goldstein et al. (1998) ran two separate analyses, one using Wechsler Adult Intelligence Scale-
Revised (WAIS-R) measures and the other using a combination of neuropsychological 
assessments; they found four-cluster solutions for both analyses, but with only weak association 
between solutions. Their intermediate clusters included moderate impairment overall, and more 
specific deficits (WAIS-R solution: low performance ability; combined solution: low abstraction 
and problem-solving ability). Also using the WAIS-R subtest scores, Seaton et al. (1999) found a 
similar solution to that of Goldstein et al. (1998), with a ‘low average’ cluster and a cluster with 
poor performance scores but average verbal scale scores. All of the above studies also reported 
the commonly found ‘normal’ and ‘globally impaired’ clusters. The neurocognitive measures 
used in these studies varied considerably; thus, it is likely that differences in cluster profiles 
reflect, at least in part, the instruments used to derive the clusters. In support of this 
interpretation, the two studies that used WAIS-R scores found the most comparable emergent 
clusters (Goldstein et al.1998; Seaton et al.1999). 
Neurocognitive clusters may be associated with clinical characteristics and community 
functioning in patients with SZ and related disorders. A report of patients with schizoaffective 
disorder (SZA) compared with clinical subtypes of SZ (paranoid, undifferentiated, and residual) 
found that patients with SZA or paranoid-type SZ had more intact cognitive functioning than 
undifferentiated- or residual-type SZ patients (Goldstein et al.2005). They also found a higher 
percentage of the SZA/paranoid-type SZ in a ‘neuropsychologically normal’ cluster. Similarly, 
Hill et al. (2002) found that patients with paranoid-subtype SZ were more likely to be included 
in a higher-performing cluster, whereas patients with negative or disorganized clinical subtypes 
were more likely to be assigned to the impaired clusters. Similar reports have also found 
associations between the neuropsychologically normal cluster, increased socialization and fewer 
hospitalizations (Palmer et al.1997; Allen et al.2003). However, Seaton et al. (1999) found no 
association between clusters on symptom profile, severity or diagnostic subtypes. 
Despite a growing literature supporting cognitive dysfunction as a key feature of bipolar disorder 
(BD), and particularly BD with psychosis (BDP), cluster approaches to characterizing cognitive 
deficits in BD have not been reported. Further, despite an ongoing nosological debate concerning 
BD and SZ, and increasing evidence of substantial clinical, biological and etiological overlap in 
these disorders, cluster approaches in neurocognition have not been applied to cross-diagnostic 
samples of patients with psychosis and affective illness. In this study we applied a cluster-
analysis approach to a large, well-characterized, cross-diagnostic sample of patients with 
psychotic disorders using a broad neurocognitive battery selected to assess multiple domains of 
cognition often reported to show deficits in psychotic disorders. We then compared emergent 
clusters on diagnosis and clinical, demographic and community functioning variables. 
Method 
Participants 
Patients with diagnoses of SZ (n = 41), SZA (n = 53) or BDP (n = 73) between the ages of 18 
and 55 years were recruited through the Schizophrenia and Bipolar Disorder Program at McLean 
Hospital. All procedures were approved by the McLean Hospital Institutional Review Board. 
Participants were recruited through in-patient units after stabilization or via fliers posted at the 
hospital. Participants had no history of substance dependence within the last year, no substance 
abuse within the past 3 months, and no history of seizure disorder or head injury with loss of 
consciousness. 
Materials 
Participants were administered clinical and neuropsychological assessments and a diagnostic 
interview. The neuropsychological battery included: Trails A and B (Trails; processing speed, 
executive functioning); the Brief Visuospatial Memory Test (BVMT; visuospatial learning and 
memory) total recall and delayed recall measures; the Stroop color and word test (Stroop; 
attention, processing speed, executive functioning) color and color–word (interference) forms; 
the Hopkins Verbal Learning Test – Revised (HVLT; verbal learning and memory) total recall 
and delayed recall measures; category fluency (verbal fluency). Raw scores were converted to 
standard scores using published normative data (Golden, 1978; Selnes et al.1991; 
Benedict, 1997; Benedict et al.1998; Gladsjo et al.1999). Standardized scores were then 
converted to Z-scores. 
Diagnosis was established using the Structured Clinical Interview for DSM-IV-TR (SCID; 
First et al.1996) completed through patient interview, medical record review, and – when 
possible – consultation with the participant's treatment provider(s). The SCID was administered 
by trained clinicians as part of a larger study on genotype and phenotype in psychotic disorders. 
SCID interviewers met routinely for reliability exercises and to discuss difficult cases and arrive 
at a consensus diagnosis. Rates of agreement were perfect (1.0) for SCID diagnoses (Öngür et 
al.2009). The same study staff conducting the cognitive assessments never administered the 
SCID. 
The assessment also included the Positive and Negative Syndrome Scale (PANSS; Kay et 
al.1987), the Young Mania Rating Scale (YMRS; Young et al.1978) and the Montgomery–
Åsberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979) to evaluate current 
psychotic and mood symptoms, and the Multnomah Community Ability Scale (MCAS; Barker et 
al.1994) to assess community functioning. The MCAS measures community functioning in 
several domains including daily living, social involvement and interest, and occupational/other 
meaningful activity. We administered a modified version, eliminating items that directly 
assessed clinical symptoms (M3, M4, M17), substance abuse (M16) and intellectual functioning 
(M2) in order to obtain a measure of community functioning that was less directly influenced by 
clinical and cognitive symptoms. The final MCAS version used in this study included 11 items 
scored in the range of one to five (a score of five indicating highest functioning) for a total of 55 
points. 
Information about medication at time of assessment was obtained from the discharge medication 
list (in- patients) or by patient report (out-patients). Chlorpromazine (CPZ) equivalents were 
calculated based on the recommendations set forth in Baldessarini (2012). 
Procedures 
All participants completed the above assessment lasting approximately 3 h broken into two 
sessions. The SCID was administered during the first session and the neurocognitive assessment 
during a second session. Clinical symptoms were assessed during either the first or second 
session. Clinical and cognitive data were collected within 1 week of each other. Diagnostic 
interviews and neuropsychological assessments were always conducted by different staff 
members; however, cognitive and symptom assessments were often conducted by the same study 
staff, and staff members were not always able to remain blind to diagnosis. 
Statistical approach 
Cluster analyses were performed in Stata (StataCorp LP, USA) using Ward's linkage with 
squared Euclidean distance. The number of clusters examined was selected by visual inspection 
of the dendrograms and confirmed by discriminant function analysis. Data were then entered into 
a K-means cluster, with the number of means selected based on results of the hierarchical cluster 
analysis and the results of the discriminant function analysis. Clusters (using K-means results) 
were then compared on demographic, clinical and cognitive variables using analysis of variance 
(ANOVA) or χ2. Post-hoc t tests with Bonferroni correction were conducted to examine pairwise 
relationships between clusters. Lastly, we conducted a series of linear regressions modeling age, 
education, CPZ equivalents, diagnosis, cluster and the diagnosis × cluster interaction to predict 
cognitive outcomes in order to examine the association of cluster with each cognitive variable 
after accounting for demographic and clinical variables, diagnosis and the interaction term. 
Results 
Cluster solutions 
All neurocognitive data were adjusted for age or age and education using published norms and 
then converted to standard (Z) scores for ease of comparison, and so that each variable 
contributed equally to the distance measure. Ward's method of cluster analysis with a squared 
Euclidean distance was applied to the BVMT total and delayed recall scores, HVLT total and 
delayed recall scores, Trails A time to completion, Trails B time to completion, category fluency 
total number generated, Stroop color test correct in 45 s, and Stroop color–word interference 
condition correct in 45 s for the total sample. The dendrogram provided evidence for two-, three- 
and four-cluster solutions, with reasonable separation between clusters. The two-cluster solution 
characterized generically ‘better’ and ‘poorer’ neurocognitive functioning, with cluster 1 scores 
between 0.5 and 1.0 standard deviations below the mean and cluster 2 scores between 1.0 and 2.5 
standard deviations below the mean. The three-cluster solution offered separation of meaningful 
groupings, with cluster 1 performing in the normal range of cognitive functioning, cluster 2 
performing at a moderate level of dysfunction, and cluster 3 performing significantly below the 
mean on all measures. The four-cluster solution further divided cluster 2 (from the three-cluster 
solution) into mixed profiles in terms of domains of dysfunction. Based on inspection of the 
dendrogram and the cognitive profiles by cluster, a four-cluster solution was selected as 
providing the best differentiation amongst clusters with meaningful groupings in terms of 
cognitive functioning. A multivariate test of group differences was performed using canonical 
linear discriminant function analysis, which confirmed that the four groups were adequately 
differentiated (p < 0.0001–p < 0.05 at each level). 
Next a K-means cluster analysis was performed specifying four clusters, entering the cognitive 
variables above. K-means is an iterative cluster approach, which allows movement of cases 
among clusters, thus constructing a more stable cluster solution. The four-cluster solution 
produced by the K-means analysis was used for all subsequent analyses. Neurocognitive profiles 
by cluster included a ‘neuropsychologically normal cluster’ (cluster 1), a globally and 
significantly impaired cluster (cluster 4), and two clusters of mixed cognitive profiles: cluster 2 
exhibited poor visuospatial learning and memory, moderate verbal learning and memory 
impairment, and relatively intact processing speed and executive function, whereas cluster 3 
exhibited poor verbal memory, verbal fluency, executive functioning and processing speed but 
intact visuospatial learning and memory. 
Cognitive characteristics by cluster 
Clusters were compared on cognitive characteristics using one-way ANOVAs (Table 1); all 
variables showed significant group differences. Bonferroni-corrected post-hoc t tests were used 
to examine pairwise comparisons between clusters (see Fig. 1 for cluster profiles). Cluster 4 
performed significantly worse on most variables than the other clusters: cluster 1 all variables 
(t = −6.23 to−20.18, p < 0.0001); cluster 2 all variables (t = −4.15 to −9.11, p < 0.01 
to p < 0.0001); cluster 3 all variables (t = −2.74 to –20.60; p < 0.05 to p < 0.0001) except 
category fluency (t = −2.22, p = 0.19) and Trails A (t = −2.21, p = 0.18). Clusters 1 and 2 
differed on BVMT and HVLT measures (t = −7.34 to −13.22, p < 0.0001) and Stroop 
interference (t = 2.94,p < 0.05); clusters did not differ on the two processing speed measures 
(Stroop color and Trails A; t = −0.84, p = 1.0; andt = −0.33, p = 1.00, respectively), Trails B 
(t = −1.96, p = 0.32) or category fluency (t = −2.05, p = 0.23). Clusters 1 and 3 differed on all 
variables (t = −4.80 to −8.26, p < 0.0001) except BVMT total and BVMT delayed recall 
(t = −1.66, p = 0.39; and t = −0.40,p = 1.0, respectively). Clusters 2 and 3 differed on all 
measures except HVLT total and delayed recall (t = −1.40, p = 0.62 andt = 0.48, p = 1.0, 
respectively) and category fluency (t = −2.51, p = 0.09) (all other variables t = −3.68 to 
11.50, p < 0.01 top < 0.0001). 
 
Fig. 1. Cogntive scores by K-means cluster. (a) Cluster 1 (‘neuropsychologically normal’). (b) 
Cluster 2 (‘processing speed/executive’). (c) Cluster 3 (‘visuospatial’). (d) Cluster 4 (‘globally 
significantly impaired’). BVMT, Brief Visuospatial Memory Test; HVLT, Hopkins Verbal 
Learning Test – Revised. 
Table 1. Cognitive scores by K-means cluster 
 Cluster 1 (n= Cluster 2 (n= Cluster 3 (n= Cluster 4 (n= F statistic 
46)  42)  35)  44)  
BVMT total  0.16 (0.85)  −2.02 (0.69)  −0.15 (0.80)  −2.60 (0.61)  F3,164 = 
146.82**** 
BVMT delayed 
recall  
0.23 (0.86)  −1.83 (0.84)  −0.16 (0.65)  −2.63 (0.56)  F3,164 = 
161.46**** 
HVLT total  0.22 (0.78)  −1.14 (0.97)  −1.47 (1.07)  −2.44 (0.66)  F3,164 = 
73.53**** 
HVLT delayed 
recall  
0.16 (0.73)  −1.30 (1.07)  −1.18 (1.08)  −2.61 (0.57)  F3,164 = 
77.48**** 
Stroop color  −0.97 (0.70)  −1.09 (0.57)  −1.71 (0.59)  −2.13 (0.64)  F3,164 = 
33.19**** 
Stroop 
interference  
−0.09 (0.85)  −0.59 (0.73)  −1.22 (0.78)  −1.70 (0.78)  F3,164 = 
36.16**** 
Category 
fluency  
−0.03 (1.02)  −0.49 (1.12)  −1.08 (0.89)  −1.59 (1.11)  F3,164 = 
19.18**** 
Trails A  0.06 (0.76)  0.01 (0.80)  −0.67 (0.56)  −1.06 (0.96)  F3,164 = 
20.58**** 
Trails B  0.05 (0.85)  −0.35 (1.08)  −1.38 (1.08)  −2.29 (0.90)  F3,164 = 
52.51**** 
Data are given as mean (standard deviation). 
BVMT, Brief Visuospatial Memory Test; HVLT, Hopkins Verbal Learning Test – Revised. 
**** p< 0.0001. 
 
Demographic and clinical comparisons by clusters 
Demographic and clinical data were compared by diagnosis prior to clustering (Table 2) and by 
cluster using one-way ANOVAs or χ2 analyses (Table 3). In terms of demographics, clusters 
differed on age and educational attainment. Post-hoc t tests with Bonferroni correction showed 
that cluster 4 was older than cluster 1 (t = 2.87, p = 0.02), and had lower educational attainment 
than clusters 1 and 2 (t = −4.07, p = 0.001, and t = −2.71, p = 0.04, respectively). Groups did not 
differ on sex, ethnicity or number of lifetime hospitalizations. 
Table 2. Demographic and clinical means by diagnosis 
 BDP (n= 73)  SZ (n= 41)  SZA (n= 53)  Test statistic 
Age, years  35.69 (10.91)  37.60 (11.15)  38.44 (10.67)  F2,164 = 1.12 
Educationa  5.26 (1.45)  4.19 (1.37)  4.65 (1.69)  F2,162 = 7.59*** 
Sex, % female  60  30  57  χ22 = 10.85** 
Ethnicity, % Caucasian  80  72  78  χ22 = 1.01 
Lifetime 
hospitalizations  
3.80 (3.01)  3.93 (2.15)  5.20 (2.84)  F2,161 = 4.48* 
CPZ, equivalents  231.06 
(222.94)  
444.10 
(321.18)  
472.77 
(317.54)  
F2,159 = 
14.57*** 
YMRS  17.36 (14.66)  13.86 (9.22)  12.94 (10.75)  F2,164 = 2.37 
MADRS  12.80 (9.48)  11.93 (8.91)  16.67 (10.42)  F2,164 = 3.62* 
PANSS total  53.65 (16.66)  67.60 (16.56)  57.63 (15.58)  F2,164 = 
10.29*** 
PANSS positive  15.14 (7.51)  19.91 (7.23)  16.37 (7.13)  F2,164 = 5.99** 
PANSS negative  10.51 (4711)  16.05 (6.70)  12.39 (4.28)  F2,164 = 
16.16*** 
PANSS general  28.00 (8.73)  31.65 (8.55)  28.87 (7.62)  F2,164 = 2.71 
MCAS  47.01 (6.34)  40.26 (7.71)  43.23 (7.42)  F2,154 = 
12.69*** 
Data are given as mean (standard deviation) unless stated otherwise. 
BDP, Bipolar disorder with psychosis; SZ, schizophrenia; SZA, schizo-affective disorder; CPZ, 
chlorpromazine; YMRS, 
Young Mania Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; PANSS, 
Positive and Negative Syndrome 
Scale; MCAS, Multnomah Community Ability Scale; SCID, Structured Clinical Interview for 
DSM-IV-TR. a Education is coded based on the SCID Education and Work History scale: 1 = 
grade 6 or less; 2 = grade 7–12 (without 
graduating); 3 = high school graduate or equivalent; 4 = part college; 5 = graduated 2 year 
college; 6 = graduated 4 year college; 
7 = part graduate/professional school; 8 = completed graduate/professional school. 
* p< 0.05, ** p< 0.01, *** p< 0.001 
 
Table 3. Demographic and clinical means by K-means cluster 
 Cluster 1 (n= 
46)  
Cluster 2 (n= 
42)  
Cluster 3 (n= 
35)  
Cluster 4 (n= 
44)  
Test statistic 
Age, years  34.00 (10.89)  37.19 (10.63)  36.89 (10.05)  40.62 (11.22)  F3,164 = 2.92* 
Educationa  5.30 (1.35)  5.00 (1.60)  4.80 (1.51)  4.11 (1.45)  F3,163 = 
5.33** 
Sex, % female  47  48  51  58  χ23 = 1.35 
Ethnicity, % 
Caucasian  
85  79  71  76  χ23 = 2.44 
Lifetime 
hospitalizations  
3.83 (2.61)  4.05 (2.51)  4.32 (4.09)  4.78 (2.00)  F3,162 = 0.95 
CPZ, 
equivalents  
229.69 
(183.07)  
350.69 
(256.70)  
294.50 
(267.58)  
514.97 
(374.16)  
F3,159 = 
8.13*** 
YMRS  12.09 (10.71)  18.00 (12.50)  12.69 (11.35)  15.89 (14.52)  F3,164 = 2.14 
MADRS  12.60 (9.44)  14.55 (10.37)  13.37 (9.32)  14.67 (10.02)  F3,164 = 0.46 
PANSS total  51.09 (14.13)  59.24 (17.50)  55.89 (16.56)  66.20 (17.61)  F3,164 = 
6.76*** 
PANSS 
positive  
13.91 (6.79)  18.10 (8.24)  15.49 (6.82)  18.62 (7.54)  F3,164 = 
4.04** 
PANSS 
negative  
10.28 (3.51)  12.40 (4.94)  12.09 (5.05)  15.22 (7.29)  F3,164 = 
6.59*** 
PANSS 
general  
26.89 (7.45)  28.74 (8.45)  28.31 (8.68)  32.36 (8.62)  F3,164 = 3.56* 
MCAS  47.02 (6.76)  42.63 (8.19)  45.06 (7.11)  42.27 (7.07)  F3,155 = 
4.01** 
Data are given as mean (standard deviation) unless stated otherwise. 
BDP, Bipolar disorder with psychosis; SZ, schizophrenia; SZA, schizo-affective disorder; CPZ, 
chlorpromazine; YMRS, 
Young Mania Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; PANSS, 
Positive and Negative Syndrome 
Scale; MCAS, Multnomah Community Ability Scale; SCID, Structured Clinical Interview for 
DSM-IV-TR.  
a Education is coded based on the SCID Education and Work History scale: 1 = grade 6 or less; 2 
= grade 7–12 (without 
graduating); 3 = high school graduate or equivalent; 4 = part college; 5 = graduated 2 year 
college; 6 = graduated 4 year college; 
7 = part graduate/professional school; 8 = completed graduate/professional school. 
* p< 0.05, ** p< 0.01, *** p< 0.001. 
 
In terms of clinical characteristics, clusters differed on CPZ equivalents at the time of testing and 
all PANSS scores and PANSS total. Post-hoc t tests showed that in all cases cluster 4 had the 
highest level of symptomatology. Compared with cluster 1, cluster 4 had significantly higher 
symptom ratings on all PANSS measures (t = 3.14 to 4.55, p = 0.01 to p < 0.0001). Cluster 4 had 
higher PANSS total scores than cluster 3 (t = 2.67, p = 0.04). Clusters did not differ on YMRS or 
MADRS scores. Cluster 4 had significantly higher CPZ dosing than clusters 1, 2 or 3 (t = 2.34 to 
4.55, p < 0.05 to p < 0.0001), which did not differ from each other on CPZ levels. Clusters 
differed in MCAS scores, with cluster 1 showing better community functioning scores than 
clusters 2 and 4 (t = −2.74, p = 0.03; and t = −3.18, p = 0.02, respectively); there were no other 
differences between clusters in terms of community functioning scores. 
Diagnoses by cluster 
All diagnoses were represented in each cluster, although they were not distributed evenly 
(χ2 = 24.71, p < 0.001) (Table 4). Patients with BDP made up 63% of cluster 1 
(‘neuropsychologically normal’), compared with 26% SZA and 11% SZ. Similarly, cluster 2 
(‘processing speed/executive’) was made up primarily of patients with BDP (45%) and SZA 
(43%), with only five patients with SZ (12%) being assigned to this cluster. Diagnoses were 
more evenly distributed in cluster 4 (‘globally-impaired’) (BDP: 25%; SZA: 36%; SZ: 39%). 
Cluster 3 (‘visuospatial’) contained 40% BDP, 20% SZA and 40% SZ. 
Table 4. Cluster assignment by diagnosisa 
 Diagnosis 
 BDP  SZ  SZA  Total 
Cluster 1 
Observed frequency  29  5  12  46 
Expected frequency  20.1  11.3  14.6  46.0 
χ2 Contribution  3.9  3.5  0.5  7.9 
Cluster 2 
Observed frequency  19  5  18  42 
Expected frequency  18.4  10.3  13.3  42.0 
χ2 Contribution  0.0  2.7  1.6  4.4 
Cluster 3 
Observed frequency  14  14  7  35 
Expected frequency  15.3  8.6  11.1  35.0 
χ2 Contribution  0.1  3.4  1.5  5.0 
Cluster 4 
Observed frequency  11  17  16  44 
Expected frequency  19.2  10.8  14.0  44.0 
χ2 Contribution  3.5  3.6  0.3  7.4 
Total 
Observed frequency  73  41  53  167 
Expected frequency  73.0  41.0  53.0  167.0 
χ2 Contribution  7.6  13.2  3.9  24.7 
BDP, Bipolar disorder with psychosis; SZ, schizophrenia; SZA, schizo-affective disorder. 
aPearson χ26 = 24.71 (p< 0.001) 
Linear regression analyses 
We conducted a series of linear regressions to examine effects of demographic (age, education) 
and clinical (CPZ equivalents) variables and diagnosis on cognitive outcomes, and to examine 
any possible diagnosis × cluster interactions. Cluster membership contributed to the model even 
after accounting for these other variables (t = 3.59 to t = 16.99, p < 0.001). Diagnosis was only a 
significant predictor of category fluency (t = −2.67, p < 0.01), and cluster membership continued 
to contribute significantly to the model. CPZ contributed only to HVLT total 
(t = −3.23, p < 0.01) and HVLT delayed recall (t = −2.98, p < 0.01). Education contributed only 
to Trails B (t = 2.25, p < 0.05). Age and the diagnosis × cluster interaction were not significant 
predictors in any model. 
Discussion 
We conducted a data-driven, exploratory hierarchical cluster analysis followed by a K-means 
cluster analysis to examine patterns of cognitive profiles in a large, cross-diagnostic sample of 
patients with psychotic disorders. A four-cluster solution provided adequate separation of the 
clusters and meaningful cognitive profiles. Cluster 1 represents a ‘neuropsychologically normal’ 
group in which all cognitive scores except Stroop color were within 0.5 standard deviations of 
the mean. Of note, we have reported previously that Stroop color scores in our samples are 
significantly lower than would be expected, even in controls, with controls scoring 
approximately 0.8 standard deviations below the mean (Lewandowski et al.2011). In examining 
the distribution of these scores, this finding did not appear to be driven by one or more outliers; 
therefore it is likely that the Stroop values here represent artificially lowered scores by half or 
more standard deviation and should be interpreted with caution. Conversely, the cognitive profile 
of cluster 4 shows all neurocognitive variables between 1 and greater than 2.5 standard 
deviations below the mean, and represents a globally and significantly impaired group. In cluster 
2 visuospatial memory was significantly impaired, but processing speed and verbal fluency did 
not differ from the neuropsychologically normal cluster, and executive functioning was relatively 
intact, with both measures approximately half a standard deviation from the mean and only one 
measure differing from cluster 1; verbal learning and memory was moderately impaired. Cluster 
3 exhibited normal visuospatial learning and memory, but differed significantly from the 
neuropsychologically normal cluster on all other variables. Cluster 3 also performed worse than 
cluster 2 on most measures (although significantly better than cluster 2 on visuospatial memory). 
Thus, the four clusters represent broadly: (1) a ‘neuropsychologically normal’ cluster; (2) a 
‘processing speed/executive’ cluster; (3) a ‘visuospatial’ cluster; and (4) a ‘global cognitive 
impairment’ cluster. 
Our finding of a neuropsychologically normal cluster and a globally and significantly impaired 
cluster is consistent with previous studies of cognitive clusters in SZ, and indicates that these 
cognitive profiles extend to other patients with psychotic disorders as well. As noted above, 
comparison of ‘mixed’ clusters with findings from previous studies is challenging, as cluster 
solutions appear to be largely dependent upon the content (and likely the psychometric 
properties) of the measures used to derive them. We found two ‘mixed’ deficit clusters, 
‘processing speed/executive’ and ‘visuospatial’, which are similar to the findings of Goldstein et 
al. (1998) and Seaton et al. (1999) who found a cluster with poor performance ability but 
relatively intact cognition otherwise, and a cluster with more broad impairment that was not as 
severe as the globally impaired cluster. Our ‘visuospatial’ cluster was similar to that of cluster 1 
from Dawes et al. (2011), which was characterized by poor visual learning and memory relative 
to other cognitive abilities. Our mixed clusters differ considerably from those of Heinrichs & 
Awad (1993); however, the measures used in their study differed considerably from ours. For 
instance, they included a motor measure, which we did not, but did not include tests of 
visuospatial learning, which we did. Thus, differences in cluster profiles may reflect 
measurement differences between studies. 
Clusters differed on several demographic characteristics, including age and education. Cluster 1 
was significantly younger than cluster 4; clusters 2, 3 and 4 did not differ from each other. 
Cluster 4 also had lower educational attainment than clusters 1 and 2. While this finding may be 
causally associated with neurocognitive performance, the direction of that relationship is not 
clear. That is, lower educational attainment could lead to poorer neurocognitive performance, or 
neurocognitive dysfunction could lead to lower educational attainment. Unfortunately, we did 
not have adequate data regarding pre-morbid intelligence quotient and were not able to examine 
the association between pre-morbid cognitive functioning and cluster membership. 
All diagnoses were represented in all cognitive clusters. Subjects with BDP were over-
represented in cluster 1 (63%) compared with subjects with SZA (26%) and subjects with SZ 
(11%), although it should be noted that of patients with SZ, 12% were assigned to the 
neuropsychologically normal cluster (cluster 1). Similarly, cluster 2 was made up primarily of 
patients with BDP (45%) or SZA (43%), with only five subjects with SZ (12%) being assigned 
to this cluster. Patients with SZ were over-represented in clusters 3 and 4, suggesting that 
patients with SZ are disproportionately more likely to exhibit widespread impairment. These 
findings suggest that patients with affective psychosis may be more likely to exhibit no cognitive 
impairment or significant impairment in one or two select domains, such as visuospatial 
processing, than patients with non-affective psychosis, who are more likely to exhibit moderate 
to severe impairments more globally. However, it is notable that cluster 4 was comprised 
somewhat more evenly of all three diagnoses (BDP = 25%; SZA = 36%; SZ = 39%), suggesting 
that a subset of patients across psychotic disorders presents with significant and global cognitive 
impairment. The interaction of cluster × diagnosis was not significant for any regression model, 
indicating that within cluster cognitive performance did not differ by diagnosis. These findings 
support the concept of a cognitive symptom dimension that cuts across diagnostic categories in 
psychosis, although the distribution of cognitive profiles may differ by diagnosis or history of 
affective symptoms. 
Clusters were associated with clinical measures of positive, negative and general symptoms, with 
cluster 4 showing the highest symptom ratings on all measures and CPZ dose; the other three 
clusters did not differ from each other. Clusters were not associated with state mania or 
depression, and were not associated with number of lifetime hospitalizations. Given the findings 
of differences in cluster membership between affective and non-affective psychoses, these 
findings suggest that the severity of state mood symptoms is not associated with cognitive 
profiles, whereas history of mood symptoms is associated with better cognitive functioning or 
more focal cognitive deficits. Cognitive profiles may be trait-like features that are more closely 
associated with other illness traits (e.g. affective versus non-affective psychosis) than with state 
symptom presentation. 
Clusters were also associated with community functioning. Cluster 1 exhibited the best 
community functioning; clusters 2, 3 and 4 did not differ from each other. These findings suggest 
that both significant cognitive impairment in select domains and more global impairment are 
associated with poor community outcomes, and support substantial work indicating that 
cognitive deficits are among the strongest predictors of outcomes in patients with psychosis (e.g. 
Green, 2006; Barch, 2009). In a cross-diagnostic sample of patients with psychosis, baseline 
cognitive functioning after an acute episode was the strongest predictor of community 
functioning after clinical recovery 6 months later (Lewandowski et al.2013). Identification of 
patients with intact versus patients with poor cognitive functioning – both patients with 
significant and widespread impairment and patients with significant deficits in select domains –
 may have significance for prognosis and treatment planning. Additionally, cognitive 
remediation programs may attempt to develop training paradigms tailored to different profiles of 
cognitive dysfunction rather than applying a ‘one size fits all’ approach. Whether or not profile-
specific remediation programming would enhance efficacy or adherence is a question that 
remains to be tested. 
Identification of more cognitively homogeneous groups may also hasten the discovery of 
neurodevelopmental or neurodegenerative processes affecting some but not all patients with any 
given diagnosis. For instance, a cluster-analytic study of neurophysiological clusters in patients 
with BD or SZ reported three profiles described as ‘globally impaired’, ‘high cognitive’ and 
‘sensory processing’ (Hall et al.2012). Clusters were similar between diagnoses, suggesting that 
neurobiological measures may be more closely linked to specific phenotypes rather than 
diagnostic groupings. 
Future studies should examine the stability of cognitive clusters over time. If clusters represent 
stable cognitive symptom profiles, then these groupings can be used to study associations with 
neurobiological measures (Seaton et al.2001). Further, their predictive validity can be studied in 
terms of clinical and functional outcomes. In a study examining the stability of cognitive clusters 
over a 3-year follow up, Heinrichs et al. (1997) found low to moderate stability of clusters 
(individual κ's ranged from 0.12 to 0.66), suggesting that some clusters were considerably more 
stable than others. The identification of stable, homogeneous groupings of patients by symptom 
dimension may lead both to better understanding of the pathophysiology of these illnesses, and 
to better diagnostic procedures and treatments to target these key symptoms. 
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